GlassScriptPhysician profile
Khaled Albasha
NPI 1932147477
$6,521.89
in general payments reported to CMS, 2019-2025
37 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $340 · 2021: $155 · 2022: $620 · 2023: $962 · 2024: $1,065 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,004.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $671.04 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Amgen INC. | $569.83 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $527.29 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $470.00 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $373.71 | 2019-2025 | Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.00 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $315.08 | 2019-2025 | Opsumit, Uptravi |
| Heartflow, INC. | $294.46 | 2023-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $255.28 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $190.32 | 2019-2025 | |
| Bardy Diagnostics, INC. | $145.00 | 2019-2021 | |
| Abbott Laboratories | $132.01 | 2019-2025 | Aveir, Mitraclip |
| Astellas Pharma US INC | $121.47 | 2019 | |
| Kestra Medical Technology Services, INC. | $106.33 | 2024-2025 | Assure Wcd |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Albasha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.